Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Identification of therapeutic strategies for melanomas with rare mitogen-activated protein kinase (MAPK) mutations.

EF 2022-23

Résumé
Cutaneous melanoma is a type of skin cancer that affects the pigment-producing cells of the skin, making them proliferate uncontrollably. Melanoma incidence rates are increasing rapidly, and it is a particularly aggressive form of cancer, underlining the need for better therapies and a better characterization of the disease. Cancer is the result of mutations in the cells’ genome. In melanoma, most of these mutations occur in the mitogen-associated protein kinase (MAPK) pathway which promotes cell proliferation. In many cases, patients have melanoma with certain mutations that can be treated with targeted drugs, blocking the growth of cancer while minimally affecting normal cells. However, there are other mutations for which there is no targeted therapy. One of these cases is when NF1, a gene which is involved in activating the MAPK pathway, is mutated. This happens in approximately 14% of melanoma cases, which have limited treatment options. We have preliminary data which suggest that a new class of drugs, pan-RAF inhibitors, may be effective at targeting these NF1 mutations, when combined with an older class of drugs, MEK inhibitors. My project will consist of testing if these drugs can synergize together to reduce cell proliferation and MAPK activation in vitro and then testing if they can reduce tumour growth in mice. This work will determine whether these new drugs will prove effective for melanoma patients with limited approved therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
488142
Name
Chay Aristophane
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of therapeutic strategies for melanomas with rare mitogen-activated protein kinase (MAPK) mutations.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Kinase; Melanoma; Nf1; Rare Mutations; Targeted Therapy
Abstract
Cutaneous melanoma is a type of skin cancer that affects the pigment-producing cells of the skin, making them proliferate uncontrollably. Melanoma incidence rates are increasing rapidly, and it is a particularly aggressive form of cancer, underlining the need for better therapies and a better characterization of the disease. Cancer is the result of mutations in the cells’ genome. In melanoma, most of these mutations occur in the mitogen-associated protein kinase (MAPK) pathway which promotes cell proliferation. In many cases, patients have melanoma with certain mutations that can be treated with targeted drugs, blocking the growth of cancer while minimally affecting normal cells. However, there are other mutations for which there is no targeted therapy. One of these cases is when NF1, a gene which is involved in activating the MAPK pathway, is mutated. This happens in approximately 14% of melanoma cases, which have limited treatment options. We have preliminary data which suggest that a new class of drugs, pan-RAF inhibitors, may be effective at targeting these NF1 mutations, when combined with an older class of drugs, MEK inhibitors. My project will consist of testing if these drugs can synergize together to reduce cell proliferation and MAPK activation in vitro and then testing if they can reduce tumour growth in mice. This work will determine whether these new drugs will prove effective for melanoma patients with limited approved therapies.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chay, Aristophane
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~